1. Introduction
The elderly have a known risk factor for infection owing to a naturally impaired immunity caused by aging and the effects of other medical conditions. Respiratory infectious diseases are within the primary ten factors of mortality among the elderly. Until 2050, the world population aged 80 years and older is anticipated to expand by more than three times up to approximately 400 million [
1,
2]. More than half of older persons in high-income nations have three or more chronic diseases, and, as fatality drops, those with multiple comorbid conditions are expected to live longer; therefore, as life expectancy rises, infections in the elderly are becoming more significant [
3,
4]. Not only does the prognosis of infections in the elderly rely on the organism involved, but it often relies often on the patients’ conditions, the degree of treatment reliance, the nutritional state, and the cognitive capacity. A geriatric examination may identify common health issues in elderly adults, such as cognitive impairment, delirium, falls, and urine incontinence, with onset or exacerbation when infections occur [
5].
Infective endocarditis (IE) is a life-threatening illness with significant mortality and complication rates in the affected patients—mostly in older patients with coexisting conditions. It is characterized by the infection of the endocardial layer, often involving the valves due to a high turbulent flow [
6], and affects around 5–15 per 100,000 individuals annually [
7]. Despite major advances in diagnosis and medical care, the death rates have remained high, hovering around 40 percent one year following the acute infection [
8]. There are exceedingly varied and non-specific manifestations on top of the notable cardiac presentation which can be associated with the immunological and embolic consequences of IE, affecting the brain, skin, bones, joints, kidneys, and eyes, among the most frequently involved organs [
9,
10,
11,
12,
13]. This systemic diversity might result in a large delay in the diagnosis of IE, severely impacting the prognosis of patients [
14,
15]. Despite significant advances in diagnosis and therapy, the fatality rates continue to be high [
16,
17,
18].
Research indicates that the proportionate rise in the prevalence of IE was the greatest among the senior population aged 65 years or older [
19]. It has been shown that the risk of endocarditis for older people is almost five times higher than that of the general population. The high frequency of undetected degenerative valve disease and the rising use of invasive procedures and implanted medical devices may be examples of such reasons [
20], which may also affect the prognosis of older people with IE [
21]. Several procedures require antibiotic prophylaxis for patients with cardiac conditions who are at a high risk for infective endocarditis, including maxillo-facial procedures and non-dental invasive procedures of the upper and lower gastrointestinal tract, genitourinary and gynecological procedures, and those of the upper and lower respiratory tract, including ear, nose, and throat (ENT) procedures and bronchoscopy [
22,
23].
Recent studies have attempted to define the features of IE in old patients, but contradictory findings have been reported, such as the belief that IE in the elderly has distinctive clinical features compared to IE in younger patients [
24,
25]. The etiology of IE seems to be influenced by the higher prevalence of certain risk factors among older persons, such as prosthetic valves or implantable devices [
26,
27]. Transesophageal echocardiography has been discovered to greatly boost the diagnostic sensitivity for IE in older individuals, allowing for immediate antimicrobial management and assuming a higher death rate due to comorbidities and the restricted utilization of surgical therapy in this population [
28,
29]. In contrast to these findings, it has been postulated that epidemiologic variables may have a bigger role in determining the clinical presentation, the echocardiographic characteristics, the incidence of complications, and the necessity of surgery [
30,
31]. Therefore, the current study aimed to observe the characteristics of patients over 65 years old who are affected by infective endocarditis in association with the antibiotic and antifungal treatment used. A secondary target was to determine the frequency of treatment resistance, treatment complications, and mortality in these patients, as compared to those younger than 65.
3. Discussion
This multicentric study managed to provide a comprehensive analysis of infective endocarditis cases from western Romania during a four-year period and described in detail the antibiotic and antifungal management of the affected patients, along with the treatment complications and risk factors for mortality. Set in the global context of infective endocarditis, the data from Romania are limited to clinical monocentric studies [
32,
33], while country-wide epidemiologic data and real-world statistics are scarcely reported or lacking. Therefore, a real estimate of the recent evolution of cases over time is a difficult estimate in the country. However, during the four-year period of the data analysis, nearly two-thirds (62.6%) of the participants in our research were older than 65. In older patients, the incidence of endocarditis was described to be about nine times greater compared to that in younger patients, although the threshold for old age is a matter of constant change and debate [
32,
33,
34]. The age distribution of endocarditis is also changing, as endocarditis mostly impacted young individuals with rheumatic valvular disease, but it now primarily affects elderly patients, as rheumatic heart disease is widely prevented through prophylaxis methods [
35]. The patients are older because the survival rate of patients with rheumatic and congenital heart disease has increased, and degenerative valvular disease is common among the elderly [
36].
In the majority of patients, the main source of infection had a vascular origin. Similar findings were reported by other studies that discovered that vascular sources of infection were present in 63% of healthcare-associated infections [
37]. The second most common cause of infection was comprised of maxillofacial, dental, and ENT interventions, which is likely due to improper prophylaxis in high-risk patients or incorrect sterile equipment usage, as documented by previous investigators [
38]. However, the identification of the infection source was difficult in many cases since one-third of the patients had negative blood cultures. Similar research reported blood culture positive rates ranging from 40 to 70 percent [
39,
40].
Similar to the current findings,
Staphylococcus spp. was also the most commonly detected microbe in the European Infective Endocarditis Registry (EURO ENDO), involved in more than 40% of the cases observed, followed by
Streptococcus and
Enterococcus spp., which were found with a smaller frequency than that in our research [
41]. It is believed that the frequency of
Staphylococcus aureus infectious endocarditis has grown, and in the industrialized world, it has become the most prevalent causal organism [
42]. For example, in a comprehensive study conducted in India, it was identified that
Staphylococcus spp. was the predominant cause, whereas rheumatic heart disease was the most prevalent cardiac substrate at risk [
43]. In our investigation,
Staphylococcus aureus was identified more often in individuals with prosthetic valve endocarditis due to the propensity of this bacterium to attach to prosthetic materials. According to several previous works of research,
Staphylococcus aureus is the primary cause of prosthetic valve endocarditis, and it was observed that
Streptococcus strains, mainly
Streptococcus bovis, are the most prevalent strains discovered in prosthetic valve endocarditis, while
Staphylococcus spp. were second in terms of frequency [
44,
45].
Echocardiography is the most often utilized imaging technique for diagnosis; therefore, transthoracic ultrasound was conducted on all patients, while transesophageal ultrasound was performed in selected patients with valvular prosthesis. Other findings suggest that more patients should receive transesophageal echocardiography even in the absence of prosthetic valve involvement [
46]. In the majority of patients with extensive vegetations and intracardiac abscess, vegetations served as the most important diagnostic criteria, as studies report that at least 60–70 percent of patients show vegetations and that close to 20% of patients have cardiac abscess, similarly to our findings [
47,
48].
In our analysis, the most common consequences were heart failure and acute renal failure, as almost one-third of patients were diagnosed with congestive heart failure, whilst approximately 13% of patients were diagnosed with cardiogenic shock and/or severe pulmonary edema at admission, in conjuncture with the epidemiologic studies reporting a decrease in the prevalence of congestive heart failure and cardiogenic shock. Acute renal failure was found in 26.9 percent of the patients who participated in this trial, much greater than the 17.7 percent of patients in the EURO ENDO study. In the EURO ENDO registry, up to 40 percent of patients had embolic events as the most common complication, whereas 44.1 percent were diagnosed with a stroke following infective endocarditis. Our analysis found a lower incidence of embolic events. The IE etiology of gram-negative bacilli related to septic shock in our patients, and this finding was also noted in other studies in which more than 40% of patients with this etiology were in septic shock [
49]. In spite of breakthroughs in diagnosis and treatment, the disease’s incidence and mortality did not decline, and the disease’s death rate had reached 20% in the previous 30 years [
50].
In our investigation, a significant mortality rate was seen in 26.9% of the patients under 65 years old and 40.5% of those older than 65. Some writers also report significant death rates between 15 and 30% [
51]. It was generally observed that mortality is closely correlated with the etiology of endocarditis, it having the highest rates in fungal endocarditis [
52]. The optimal antifungal treatment is still a matter of debate. The
Candida species may build biofilms on native and artificial heart valves, which can impair the antifungal effectiveness of antifungal medications used to treat
Candida endocarditis. Voriconazole is effective against a broad range of clinically significant fungal infections, such as
Candida,
Aspergillus, and
Fusarium. Amphotericin B has been used to treat endocarditis caused by
Aspergillus. Amphotericin B is less toxic than traditional amphotericin and may be provided at greater dosages, making it particularly useful for patients with compromised renal function or who develop nephrotoxicity when taking standard amphotericin [
53]. Amphotericin B cannot successfully penetrate and treat FE-associated vegetations on its own. Itraconazole and Caspofungin are effective against resistant
Aspergillus infections. Compared to other antifungal medicines, echinocandins are less toxic and have fewer drug interactions. They are equally effective as Amphotericin B in treating non-neutropenic individuals infected with
Aspergillus [
54].
Even though timely antibacterial and antifungal management can be initiated, there are multiple consequences associated with medical treatment in the elderly. As renal function diminishes with age, elderly people also have a reduced renal clearance that may raise the risk of nephrotoxicity or systemic side effects when renally cleared antimicrobials are chosen without dosage modification, as observed in our patients. Clinicians should be aware that nephrotoxic antibiotics such as aminoglycosides and vancomycin are more likely to induce acute kidney failure in older patients with diabetes or who take diuretics and ACE inhibitors [
55]. Another antibiotic, Daptomycin, a quickly bactericidal cyclic lipopeptide, has been approved for the treatment of right-sided staphylococcal endocarditis and seems to be well tolerated by the elderly, although it is much more costly than vancomycin because of its proven efficacy against bacterial biofilm. It might be regarded as the treatment of choice in patients with significantly compromised renal function and in cases of IE affecting cardiac implanted electronic devices [
56].
Considering the scarcity of data and epidemiological studies about infective endocarditis in Romania, this research brings important new information about the evolution of such cases and their treatment in a multicentric setting. Therefore, the current study’s main strength is the detailed analysis of IE during the last four years in western Romania. Nevertheless, several limitations are worth mentioning. First of all, the retrospective design relying strongly on patient recordkeeping and the quality of data digitally copied from paper records can allow for human errors while reporting the data. Another limitation is the sample size that was restricted by the time spread of the retrospective analysis and the participation of the four clinics involved in the treatment of IE from the western Romanian region; therefore, the current results might not confidently represent the characteristics and outcomes of all patients affected in the country of interest.
4. Materials and Methods
4.1. Study Design and Ethical Considerations
A multicenter research study was designed as a retrospective study of hospitalized patients with infective endocarditis. The setting comprised three tertiary hospitals in Western Romania, where patients were admitted to the Cardiology and Internal Medicine Departments in the period starting from January 2018 until December 2021. The research protocol was approved by the Ethics Committee of the “Victor Babes” University of Medicine and Pharmacy of Timisoara, Romania and by the Ethics Committee of the hospitals included in the current study.
4.2. Inclusion Criteria and Study Variables
We used a convenience sampling approach to determine the ideal sample size, which was determined to be at least 385 patients, for a 5% margin of error at a 95% level of confidence and an approximate incidence of 3–10 in 100,000 patients per year [
57]. A database and patient paper record search were conducted to determine the cases of infective endocarditis from patients admitted to the three hospitals participating in the current study. The diagnosis of infective endocarditis was made by the use of electrocardiograms, imagistic findings (cardiac transthoracic or transesophageal ultrasound and computed tomography), and bacterial identification by conventional cultures and PCR. Other detailed assessments were performed to determine the clinical evolution of affected patients and to observe whether organ failure occurs. Patients older than 65 who were confirmed as having endocarditis were included in the elderly group “≥65 years”, while those who were younger than 65 were defined as adults “<65 years”. Patients with incomplete records or those lacking consent were removed from the study. Other patient-specific characteristics were retrieved from paper and database records, such as the recent history of dental, maxillo-facial, and ENT procedures and the history of valvuloplasty or valve replacement surgery.
The variables considered to be relevant to the current study comprised the following: (1) patient background analysis: age, sex, body mass index, tobacco and alcohol use, and comorbidities; (2) treatment options and patient outcomes: days from symptom onset until hospitalization, localization on native and prosthetic valves, tests performed for infection identification, the presence of heart failure on admission, the severity of valvular regurgitation, oxygen supplementation, and outcomes (intensive care unit admission, days spent in the ICU, days between symptom onset and death, days between symptom onset and ICU admission, mortality, and days until discharge); (3) etiology, procedures, interventions, and complications; (4) microbial identification, antibacterial and antifungal management, and medical treatment complications; (5) risk factor analysis.
4.3. Statistical Analysis
The statistical analysis was conducted using IBM SPSS version 27 (IBM Corp, Armonk, NY, USA) and MedCalc for Windows, version 20 (MedCalc Software, Ostend, Belgium). This determined the absolute and relative frequencies of the categorical variables. The Chi-square test and Fisher’s test were used to compare proportions, and the Mann–Whitney test was used to compare nonparametric group differences. Using the Student’s t-test, the mean and standard deviations of continuously distributed values with a normal distribution were compared (unpaired, independent samples). In conclusion, a multivariate analysis adjusted for confounding variables was conducted to identify the independent risk factors for death. The significance criterion was established at a 0.05 alpha value.